Lataa...
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
BACKGROUND: Entecavir-resistance mutations are commonly induced by entecavir treatment in chronic hepatitis B patients. However, entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations induced by sequential or combination treatment with lamivudine and adefovir dipivoxil have never been r...
Tallennettuna:
| Julkaisussa: | Ann Clin Microbiol Antimicrob |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4832522/ https://ncbi.nlm.nih.gov/pubmed/27079793 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12941-016-0138-0 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|